Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above

NCT04546724 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT04546724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04546724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
September 17, 2020
Completion date
October 15, 2021
Enrollment
4,128 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection